MediWound Ltd.
MDWD · NASDAQ
Market closed$14.60$-0.010000 (-0.07%)After hours $14.44 · -1.10%
Key statistics
Previous close$14.61
Open$14.55
Day high$14.77
Day low$14.49
52-week high$21.11
52-week low$13.54
Market cap158.59M
Volume60.75K
Average volume87.60K
P/E ratio-6.46
Forward P/E—
EPS-2.26
Dividend yield0.00%
Market context
Why it moved
MDWD experienced a marginal decline today, likely reflecting routine profit-taking or low trading volume with no significant company-specific catalysts driving notable price action.
What is happening
Recent company-specific developments and publisher coverage.
TradingView · July 2, 2026Three Years of War Changed What Governments Buy. One Player is Already Winning Contracts (NASDAQ: MDWD)The Jerusalem Post · June 17, 2026Israeli treatment that spared burn surgeries now aims to save limbsPluang · May 29, 2026Industrial Alliance lowers MediWound price targ...Moomoo · May 29, 2026A. G. P. Maintains MediWound(MDWD.US) With Buy Rating, Cuts Target Price to $22Quiver Quantitative · May 27, 2026MEDIWOUND ($MDWD) Releases Q1 2026 EarningsQuiver Quantitative · April 13, 2026MediWound Highlights U.S. Expert Consensus Supporting EscharEx® Strategy for Chronic Wound DebridementInvesting.com · April 13, 2026MediWound highlights consensus supporting debridement strategySimply Wall Street · January 14, 2026We Think MediWound (NASDAQ:MDWD) Can Afford To Drive Business Growth Benzinga · May 28, 2026Oppenheimer Maintains Outperform on MediWound, Lowers Price Target to $32 Mt Newswire · May 28, 2026Oppenheimer Adjusts MediWound Price Target to $32 From $33, Maintains Outperform Rating Benzinga · May 27, 2026MediWound Reports Q1 2026 Results: Full Earnings Call Transcript Benzinga · May 27, 2026MediWound Affirms FY2026 Sales Guidance of $24.000M-$26.000M vs $24.759M Est Benzinga · May 27, 2026MediWound Q1 EPS $(0.23) Beats $(0.64) Estimate, Sales $1.475M Miss $3.117M Estimate Benzinga · April 7, 2026MediWound Showcases New Wound Healing Data Across 3 Global Conferences, EscharEx Study Results Back Late-Stage Trials And Expansion Into Diabetic Ulcers Benzinga · March 5, 2026MediWound Affirms FY2028 Sales Guidance of $50.000M-$55.000M Benzinga · March 5, 2026MediWound Affirms FY2027 Sales Guidance of $32.000M-$35.000M